SI2038294T1 - 18-metil-19-nor-androst-4-en-17,17-spiroetri (18-metil-19-nor-20-spiroks-4-en-3-oni) in tudi farmacevtski pripravki,ki jih vsebujejo - Google Patents

18-metil-19-nor-androst-4-en-17,17-spiroetri (18-metil-19-nor-20-spiroks-4-en-3-oni) in tudi farmacevtski pripravki,ki jih vsebujejo

Info

Publication number
SI2038294T1
SI2038294T1 SI200730533T SI200730533T SI2038294T1 SI 2038294 T1 SI2038294 T1 SI 2038294T1 SI 200730533 T SI200730533 T SI 200730533T SI 200730533 T SI200730533 T SI 200730533T SI 2038294 T1 SI2038294 T1 SI 2038294T1
Authority
SI
Slovenia
Prior art keywords
methyl
spiroether
spirox
androst
same
Prior art date
Application number
SI200730533T
Other languages
English (en)
Inventor
Rolf Bohlmann
Joachim Kuhnke
Jan Hubner
Norbert Gallus
Frederik Menges
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2038294(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of SI2038294T1 publication Critical patent/SI2038294T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
SI200730533T 2006-06-29 2007-06-29 18-metil-19-nor-androst-4-en-17,17-spiroetri (18-metil-19-nor-20-spiroks-4-en-3-oni) in tudi farmacevtski pripravki,ki jih vsebujejo SI2038294T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
EP07765033A EP2038294B1 (de) 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
PCT/EP2007/005893 WO2008000521A1 (de) 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number Publication Date
SI2038294T1 true SI2038294T1 (sl) 2011-04-29

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730533T SI2038294T1 (sl) 2006-06-29 2007-06-29 18-metil-19-nor-androst-4-en-17,17-spiroetri (18-metil-19-nor-20-spiroks-4-en-3-oni) in tudi farmacevtski pripravki,ki jih vsebujejo

Country Status (41)

Country Link
US (1) US7846917B2 (sl)
EP (1) EP2038294B1 (sl)
JP (1) JP5326085B2 (sl)
KR (1) KR101440640B1 (sl)
CN (1) CN101511857B (sl)
AR (1) AR061736A1 (sl)
AT (1) ATE490967T1 (sl)
AU (1) AU2007263944B2 (sl)
BR (1) BRPI0713934A2 (sl)
CA (1) CA2656443C (sl)
CL (1) CL2007001919A1 (sl)
CO (1) CO6150134A2 (sl)
CR (1) CR10548A (sl)
CY (1) CY1111658T1 (sl)
DE (2) DE102006030416A1 (sl)
DK (1) DK2038294T3 (sl)
DO (1) DOP2008000089A (sl)
EC (1) ECSP089014A (sl)
ES (1) ES2357698T3 (sl)
GT (1) GT200800307A (sl)
HK (1) HK1133659A1 (sl)
HN (1) HN2008001934A (sl)
HR (1) HRP20110161T1 (sl)
IL (1) IL195935A0 (sl)
MA (1) MA30596B1 (sl)
MX (1) MX2009000082A (sl)
MY (1) MY155015A (sl)
NO (1) NO20090459L (sl)
NZ (1) NZ573951A (sl)
PE (1) PE20080995A1 (sl)
PL (1) PL2038294T3 (sl)
PT (1) PT2038294E (sl)
RS (1) RS51722B (sl)
RU (1) RU2440365C2 (sl)
SI (1) SI2038294T1 (sl)
TN (1) TNSN08518A1 (sl)
TW (1) TWI413645B (sl)
UA (1) UA94952C2 (sl)
UY (1) UY30451A1 (sl)
WO (1) WO2008000521A1 (sl)
ZA (1) ZA200900673B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
AU2013251842A1 (en) * 2012-04-23 2014-11-06 Bayer Pharma Aktiengesellschaft Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
WO2015055789A1 (en) 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
AU2014336286A1 (en) * 2013-10-18 2016-03-24 Bayer Oy Intrauterine delivery system
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1148061B1 (en) 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

Also Published As

Publication number Publication date
HK1133659A1 (sl) 2010-04-01
HRP20110161T1 (hr) 2011-04-30
HN2008001934A (es) 2012-01-17
CY1111658T1 (el) 2015-10-07
WO2008000521A1 (de) 2008-01-03
MA30596B1 (fr) 2009-07-01
RU2009102772A (ru) 2010-08-10
JP2009541405A (ja) 2009-11-26
CR10548A (es) 2009-01-27
TW200811193A (en) 2008-03-01
UA94952C2 (uk) 2011-06-25
CO6150134A2 (es) 2010-04-20
IL195935A0 (en) 2009-09-01
US7846917B2 (en) 2010-12-07
GT200800307A (es) 2009-11-03
DE502007005902D1 (de) 2011-01-20
EP2038294B1 (de) 2010-12-08
CA2656443C (en) 2014-10-07
AU2007263944A1 (en) 2008-01-03
JP5326085B2 (ja) 2013-10-30
MY155015A (en) 2015-08-28
RU2440365C2 (ru) 2012-01-20
CN101511857A (zh) 2009-08-19
CA2656443A1 (en) 2008-01-03
ZA200900673B (en) 2010-04-28
ECSP089014A (es) 2009-01-30
CN101511857B (zh) 2012-10-31
UY30451A1 (es) 2008-01-31
PL2038294T3 (pl) 2011-05-31
RS51722B (en) 2011-10-31
KR101440640B1 (ko) 2014-09-22
AR061736A1 (es) 2008-09-17
BRPI0713934A2 (pt) 2012-12-04
TNSN08518A1 (en) 2010-04-14
EP2038294A1 (de) 2009-03-25
DK2038294T3 (da) 2011-03-28
ES2357698T3 (es) 2011-04-28
MX2009000082A (es) 2009-01-23
NZ573951A (en) 2011-06-30
CL2007001919A1 (es) 2008-05-16
TWI413645B (zh) 2013-11-01
PT2038294E (pt) 2011-03-14
NO20090459L (no) 2009-03-10
DE102006030416A1 (de) 2008-01-03
PE20080995A1 (es) 2008-10-03
DOP2008000089A (es) 2009-02-15
KR20090021294A (ko) 2009-03-02
AU2007263944B2 (en) 2013-07-18
ATE490967T1 (de) 2010-12-15
US20080153787A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
GB2451769B (en) Devices, systems, and methods for medicament delivery
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
EP1972251A4 (en) CAPSULE TYPE CONTAINER AND ADMINISTRATION METHOD USING THE SAME
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
GB0516069D0 (en) Pharmaceutical and use thereof
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
EP2151439A4 (en) NITROGENIC AROMATIC 6-LOW CINNAMENT AND ACTIVE SUBSTANCE THEREOF
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
IL189172A0 (en) Cercosporamide derivatives and pharmaceutical compositions containing the same
IL188011A0 (en) Spiro-benzimidazole derivatives and pharmaceutical compositions containing the same
IL190063A (en) The history of cycloalkanes is preserved, their medicinal preparations and their uses
GB2456245B (en) Devices,systems and methods for medicament delivery
ZA200808769B (en) Pharmaceutical compostion containing the NMB0938 protein